a b s t r a c t
a b s t r a c t 25 The potent ability of small interfering RNA (siRNA) to inhibit the expression of complementary RNA tran- 26 scripts is being exploited as a new class of therapeutics for diseases including HIV. However, efficient 27 delivery of siRNAs remains a key obstacle to successful application. A targeted intracellular delivery 28 approach for siRNAs to specific cell types is highly desirable. HIV-1 infection is initiated by the interac- 29 tions between viral glycoprotein gp120 and cell surface receptor CD4, leading to fusion of the viral mem- 30 brane with the target cell membrane. Once HIV infects a cell it produces gp120 which is displayed at the 31 cell surface. We previously described a novel dual inhibitory anti-gp120 aptamer-siRNA chimera in 32 which both the aptamer and the siRNA portions have potent anti-HIV activities. We also demonstrated 33 that gp120 can be used for aptamer mediated delivery of anti-HIV siRNAs. 34 Here we report the design, construction and evaluation of chimerical RNA nanoparticles containing a 35 HIV gp120-binding aptamer escorted by the pRNA of bacteriophage phi29 DNA-packaging motor. We 36 demonstrate that pRNA-aptamer chimeras specifically bind to and are internalized into cells expressing 37 HIV gp120. Moreover, the pRNA-aptamer chimeras alone also provide HIV inhibitory function by block- 38 ing viral infectivity. The Ab 0 pRNA-siRNA chimera with 2 0 -F modified pyrimidines in the sense strand not 39 only improved the RNA stability in serum, but also was functionally processed by Dicer, resulting in 40 specific target gene silencing. Therefore, this dual functional pRNA-aptamer not only represents a poten- 41 tial HIV-1 inhibitor, but also provides a cell-type specific siRNA delivery vehicle, showing promise for 42 systemic anti-HIV therapy. anti-HIV activities [22] . We also demonstrated that gp120 ex-72 pressed on the surface of HIV infected cells can be used for aptamer 73 mediated delivery of anti-HIV siRNAs [23] . Therefore the 74 anti-gp120 aptamers represent a promising class of antiviral 75 agents which can also function as siRNA delivery vehicles. [40] . The pRNA molecules were named as previously 140 described [24] . Specifically, the pRNA molecules were identified by Biotechnologies).
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The sense strands of the pRNA-siRNA chimeras are underlined.
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The italic UU is the linker between the aptamer and siRNA portions.
170
The bold nucleotides indicate aptamer sequence. The transcribed aptamer and pRNA-aptamer chimeras were or CHO-EE cells (E) were grown in 35 mm plates and incubated with a 100 nM concentration of Cy3-labeled pRNA-A-1 D4 chimera in culture media for real-time live-cellconfocal microscopy analysis. The images were collected at 20 min intervals using 40Â magnification. After 5 h incubation with 100 nM of Cy3-labeled chimera, cells were subsequently stained with Hoechst 33342 (nuclear dye for live cells) and then imaged using real-time confocal microscopy. Fig. 3 . The inhibition of HIV-1 infection mediated by pRNA-aptamer chimeras. Both anti-gp120 aptamer and pRNA-aptamer chimera neutralized HIV-1 infection in HIV infected human PBMCs (NL4-3 strain) culture. Data represent the average of triplicate measurements of p24. Ba 0 pRNA-gp120 aptamer chimera D4 inhibits HIV-1 infection of human PBMCs with comparable inhibitory potency as original A-1 aptamer. Aptamer A-5 that has previously been shown to have poor affinity for gp120 is used as a negative control. P values for the effects of A-1 and pRNA-aptamer chimera are indicated and were calculated as described in Section 2. Cy3-labeled pRNA-A-1 D4 chimera (Fig. 2D ). These cells express assayed for viral p24 antigen levels (Fig. 3) . The results showed 433 that the Ba 0 pRNA-gp120 aptamers (pRNA-A-1 D4) inhibited HIV- what reduced the efficiency of dimerization (Fig. 6A ).
507
The in vitro Dicer assay [47] was also performed to verify that 508 Dicer can process the siRNA portion after dimer formation 509 (Fig. 6B) In the present study, we therefore took advantages of the gp120 
